Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

3-Dimensional Pharmaceuticals discloses new serine protease inhibitors

Dec. 11, 1997

Potent, orally active gpIIb/IIIa receptor antagonist for once-daily administration

Dec. 2, 1997

Toyama's antiplatelet agent progresses to clinical studies

Nov. 28, 1997

Antiplatelet and antithrombotic effects of NSL-9403

Nov. 28, 1997

FACT study results reported

Nov. 27, 1997

Expanded use approved for ReoPro in Europe

Nov. 26, 1997

NDA filed in U.S. for Otsuka antiplatelet agent

Nov. 26, 1997

Agrylin approved in Canada

Nov. 25, 1997

Lilly claims antithrombotic diamides

Nov. 24, 1997

FDA clears Plavix

Nov. 19, 1997

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...